Steve Warnecke - Evolutionary Genomics CEO, Chairman

All Insiders USA . 
Stock . Evolutionary Genomics . Stakeholders . Insider . Steve Warnecke
FNAM Stock  USD 0.0002  0.00  0.00%   

Insider

Steve Warnecke is CEO, Chairman of Evolutionary Genomics
Age 66
Phone720 900 8666
Webhttps://www.evolgen.com

Evolutionary Genomics Management Efficiency

The company has return on total asset (ROA) of (0.4538) % which means that it has lost $0.4538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (145.2667) %, meaning that it created substantial loss on money invested by shareholders. Evolutionary Genomics' management efficiency ratios could be used to measure how well Evolutionary Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
Evolutionary Genomics currently holds 3.74 M in liabilities with Debt to Equity (D/E) ratio of 1.81, which is about average as compared to similar companies. Evolutionary Genomics has a current ratio of 9.65, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Evolutionary Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Evolutionary Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evolutionary Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evolutionary to invest in growth at high rates of return. When we think about Evolutionary Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Irene BrittVictorias Secret Co
58
Lukas HovorkaBarrick Mining
52
Todd SchivelyCedar Realty Trust
N/A
Lauren PetersVictorias Secret Co
59
Melinda McAfeeVictorias Secret Co
53
Allison PetersonBest Buy Co
45
Fernando GarciaRH
N/A
Brian LeinbachVictorias Secret Co
N/A
Deborah DiSanzoBest Buy Co
60
Matthew FurmanBest Buy Co
N/A
Nicholas PartenzaCedar Realty Trust
N/A
Christine RuppVictorias Secret Co
55
Peter SallickRH
N/A
Alex LouwNational Vision Holdings
N/A
Michael FranklinCedar Realty Trust
42
Brad CohenCedar Realty Trust
N/A
Stefan DubanRH
42
Jakki HausslerBarrick Mining
64
Richard SchulzeBest Buy Co
84
Jacqueline HernandezVictorias Secret Co
54
Christina HargartenRH
45
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. Evolutionary Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people. Evolutionary Genomics [FNAM] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-145.27
Return On Asset-0.45

Evolutionary Genomics Leadership Team

Elected by the shareholders, the Evolutionary Genomics' board of directors comprises two types of representatives: Evolutionary Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolutionary. The board's role is to monitor Evolutionary Genomics' management team and ensure that shareholders' interests are well served. Evolutionary Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolutionary Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Steve Warnecke, CEO, Chairman
Walter Messier, CTO, Founder

Evolutionary Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evolutionary Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-145.27
Return On Asset-0.45
Current Valuation9.18 M
Shares Outstanding6.66 M
Shares Owned By Insiders32.60 %
Price To Earning(3.79) X
Price To Sales352.91 X
Gross Profit(1.23 M)
EBITDA(1.84 M)
Net Income(2.79 M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet

Other Information on Investing in Evolutionary Pink Sheet

Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY